[1] 国家心血管病中心.中国心血管健康与疾病报告-2023,2023[M].北京:中国协和医科大学出版社,2024. National Center for Cardiovascular Diseases.Report on Cardiovascular Health and Diseases in China-2023,2023[M].Beijing:China Union Medical College Press,2024. [2] YANCY C W,JESSUP M,BOZKURT B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America[J].Circulation,2017,136(6):e137-e161. [3] NAKAMURA M,SADOSHIMA J.Mechanisms of physiological and pathological cardiac hypertrophy[J].Nat Rev Cardiol,2018,15(7):387-407. [4] WILD A R,SINNEN B L,DITTMER P J,et al.Synapse-to-nucleus communication through NFAT is mediated by L-type Ca(2+)channel Ca(2+)spike propagation to the soma[J].Cell Rep,2019,26(13):3537-3550.e4. [5] 柳长华主编.神农本草经——日森立之辑本[M].北京:北京科学技术出版社,2016. LIU CHANG HUA editor.Shennong Bencao Jing——Japan SEN LI ZHI[M].Beijing:Beijing Science and Technology Publishing Press,2016. [6] 国家药典委员会.中华人民共和国药典-四部——2020年版[M].北京:中国医药科技出版社,2020. Chinese Pharmacopoeia Commission.Chinese pharmacopoeia(Ch.P)volume IV——2020 edition[M].Beijing:China Pharmaceutical Science and Technology Press,2020. [7] ZHANG C,SHAN X L,LIAO Y L,et al.Effects of sta-chydrine on norepinephrine-induced neonatal rat cardiac myocytes hypertrophy and intracellular calcium transients[J].BMC Complement Altern Med,2014,14:474. [8] LIANG Y,XIA L,LU S,et al.A new mechanism of therapeutic effect of stachydrine on heart failure by inhibiting myocardial ferroptosis[J].Eur J Pharmacol,2023,954:175881. [9] MARTIN T G,JUARROS M A,LEINWAND L A.Regression of cardiac hypertrophy in health and disease:Mechanisms and therapeutic potential[J].Nat Rev Cardiol,2023,20(5):347-363. [10] YIN Z,WANG X,ZHANG L,et al.Aspirin attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting the Ca2+/calcineurin-NFAT signaling pathway[J].Cardiovasc Ther,2016,34(1):21-29. [11] LI N,SI B,JU J F,et al.Nicotine induces cardiomyocyte hypertrophy through TRPC3-mediated Ca(2+)/NFAT signalling pathway[J].Can J Cardiol,2016,32(10):1260.e1-1260.e10. [12] CARDOSO V,CHESNÉ J,RIBEIRO H,et al.Neuronal regulation of type 2 innate lymphoid cells via neuromedin U[J].Nature,2017,549(7671):277-281. [13] PARRA V,ROTHERMEL B A.Calcineurin signaling in the heart:The importance of time and place[J].J Mol Cell Cardiol,2017,103:121-136. [14] MOLKENTIN J D.Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs[J].Cardiovasc Res,2004,63(3):467-475. [15] LI S J,WANG J,MA L,et al.Cooperative autoinhibition and multi-level activation mechanisms of calcineurin[J].Cell Res,2016,26(3):336-349. [16] SHOU J,JING J,XIE J,et al.Nuclear factor of activated T cells in cancer development and treatment[J].Cancer Lett,2015,361(2):174-184. [17] SUZUKI H,KATANASAKA Y,SUNAGAWA Y,et al.Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy by regulating the interaction between p300 and GATA4[J].Biochim Biophys Acta,2016,1862(9):1544-1557. [18] XIA Y,MCMILLIN J B,LEWIS A,et al.Electrical stimulation of neonatal cardiac myocytes activates theNFAT3andGATA4pathways and up-regulates the adenylosuccinate synthetase 1 gene[J].J Biol Chem,2000,275(3):1855-1863. [19] OKA T,MAILLET M,WATT A J,et al.Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy,compensation,and myocyte viability[J].Circ Res,2006,98(6):837-845. [20] WANG J,PARADIS P,ARIES A,et al.Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4[J].Mol Cell Biol,2005,25(22):9829-9844. [21] ZHU X,FANG J,GONG J,et al.Cardiac-specific EPI64C blunts pressure overload-induced cardiac hypertrophy[J].Hypertension,2016,67(5):866-877. |